Trials / Completed
CompletedNCT01636401
Efficacy and Safety of 400 μg Twice Daily of Aclidinium Bromide vs. Placebo When Administered to Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- —
- Sponsor
- Daewoong Pharmaceutical Co. LTD. · Industry
- Sex
- All
- Age
- 40 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study was to observe the Efficacy and safety of 400 μg twice daily of aclidinium bromide vs. placebo when administered to patients with moderate to severe chronic obstructive pulmonary disease (COPD).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | aclidinium bromide 400 μg | |
| DRUG | aclidinium bromide placebo |
Timeline
- Start date
- 2012-08-01
- Primary completion
- 2013-05-01
- Completion
- 2013-05-01
- First posted
- 2012-07-10
- Last updated
- 2013-08-21
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT01636401. Inclusion in this directory is not an endorsement.